SCHEMBL11919936

SCHEMBL11919936

C=CCn1c(SCc2nc(-c3ccc(CC)cc3)no2)nnc1-c1ccncc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.58
▸ HDAC3 O15379 2/20 0.56
▸ PTK2 Q05397 2/20 0.56
▸ HDAC1 Q13547 2/20 0.56
▸ HDAC2 Q92769 2/20 0.56
▸ HDAC8 Q9BY41 2/20 0.56
▸ HDAC6 Q9UBN7 2/20 0.56
▸ GAA P10253 1/20 0.55
▸ TNKS2 Q9H2K2 9/20 0.54
▸ MAPT P10636 4/20 0.54
▸ TNKS O95271 4/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ THRB P10828 1/20 0.54
▸ TP53 P04637 4/20 0.54
▸ LMNA P02545 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HTT P42858 1/20 0.52
▸ CYP3A4 P08684 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919921 0.78 TNKS2 (0.76) NPSR1GAATNKS2MAPTTNKS
SCHEMBL11919932 0.73 LMNA (0.74) NPSR1GAATNKS2MAPTTNKS
SCHEMBL11920017 0.73 MAPT (0.80) NPSR1TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL1544573 0.73 SMN1; SMN2 (0.59) NPSR1GAATNKS2MAPTTNKS
SCHEMBL17695674 0.72 GSK3B (0.76) MAPTSMN1; SMN2TP53LMNAMEN1
SCHEMBL1543852 0.71 ALDH1A1 (0.64) NPSR1GAAMAPTSMN1; SMN2LMNA
SCHEMBL13046998 0.70 NPSR1 (0.90) NPSR1TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919905 0.70 NPSR1 (0.77) NPSR1TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919901 0.70 TP53 (1.00) NPSR1GAATNKS2MAPTTNKS
SCHEMBL11919943 0.69 NPSR1 (0.75) NPSR1TNKS2MAPTTNKSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 NPSR1 4727/4885HDAC3 3947/4885PTK2 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback